Showing results (151-160 of 196) with videos related to
Sort By:
Pageof 20
Journal of Neuro-Oncology|June 23, 2009
Atypical choroid plexus papilloma: clinical experience in the CPT-SIOP-2000 studyBrigitte Wrede, Martin Hasselblatt, Ove Peters, et al.Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 3, 2010
Intravenous busulfan plus melphalan is a highly effective, well-tolerated preparative regimen for autologous stem cell transplantation in patients with advanced lymphoid malignanciesPartow Kebriaei, Timothy Madden, Reza Kazerooni, et al.Bone Marrow Transplantation|September 28, 2024
High activity of the new myeloablative regimen of gemcitabine/clofarabine/busulfan for allogeneic transplant for aggressive lymphomasJeremy Ramdial, Ruitao Lin, Peter F Thall, et al.Journal of Neuro-Oncology|August 10, 2015
Methotrexate administration directly into the fourth ventricle in children with malignant fourth ventricular brain tumors: a pilot clinical trialDavid I Sandberg, Michael Rytting, Wafik Zaky, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 20, 2009
Phase II multicenter trial of imatinib in 10 histologic subtypes of sarcoma using a bayesian hierarchical statistical modelRashmi Chugh, J Kyle Wathen, Robert G Maki, et al.Blood|October 5, 2011
Donor-specific anti-HLA Abs and graft failure in matched unrelated donor hematopoietic stem cell transplantationStefan O Ciurea, Peter F Thall, Xuemei Wang, et al.Practical Radiation Oncology|January 3, 2023
A Prospective Study of Conventionally Fractionated Dose Constraints for Reirradiation of Primary Brain Tumors in AdultsSusan L McGovern, Dershan Luo, Jason Johnson, et al.Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 16, 2010
Clofarabine ± fludarabine with once daily i.v. busulfan as pretransplant conditioning therapy for advanced myeloid leukemia and MDSBorje S Andersson, Benigno C Valdez, Marcos de Lima, et al.Cancer|September 3, 2011
A randomized phase 2 trial of a preparative regimen of bortezomib, high-dose melphalan, arsenic trioxide, and ascorbic acidManish Sharma, Hassan Khan, Peter F Thall, et al.Cancer|December 11, 2020
Conditional survival among patients with oropharyngeal cancer treated with radiation therapy and alive without recurrence 5 years after diagnosisKristina R Dahlstrom, Juhee Song, Peter F Thall, et al.Pageof 20